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Abstract: Dietary intervention is a challenge in clinical practice because of inter-individual variability
in clinical response. Gut microbiota is mechanistically relevant for a number of disease states
and consequently has been incorporated as a key variable in personalised nutrition models within
the research context. This paper aims to review the evidence related to the predictive capacity of
baseline microbiota for clinical response to dietary intervention in two specific health conditions,
namely, obesity and irritable bowel syndrome (IBS). Clinical trials and larger predictive modelling
studies were identified and critically evaluated. The findings reveal inconsistent evidence to support
baseline microbiota as an accurate predictor of weight loss or glycaemic response in obesity, or as
a predictor of symptom improvement in irritable bowel syndrome, in dietary intervention trials.
Despite advancement in quantification methodologies, research in this area remains challenging
and larger scale studies are needed until personalised nutrition is realistically achievable and can be
translated to clinical practice.
Keywords: personalised nutrition; microbiota; dietary intervention; obesity; irritable bowel syndrome;
gastrointestinal symptoms
1. Introduction
Diet is a modifiable risk factor for many non-communicable diseases and there is a high level
of evidence supporting the efficacy of dietary interventions for both influencing disease risk and
improving disease outcomes. For example, dietary intervention can reduce cardiovascular disease
risk by 60% [1] and can successfully reduce gastrointestinal (GI) symptoms in at least 50% of patients
with irritable bowel syndrome (IBS) [2]. However, individual variability in response to treatment is
increasingly recognised, and this is reflected in the highly variable response rates in clinical trials of
dietary interventions, particularly in obesity [3], cardiovascular disease [4] and IBS [2].
Personalised nutrition essentially enables the tailoring of dietary advice to the individual level
through the incorporation of data related to specific biological pathways driving that individual’s
health or disease status, ultimately optimising the effectiveness of the advice. A comprehensive
understanding of clinical conditions and underlying disease mechanisms is often required, including
the genetic variants of the patient and the extent to which these variants interact with diet to affect
disease risk and treatment in diverse populations.
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Personalised nutrition models integrate a variety of host-specific variables including current
diet, biological or phenotypical characteristics of the individual (age, stage of life, gender, body mass
index (BMI), disease or health status) and genotypic characteristics. An understanding of epigenetics
(regulation of gene expression) is also often included. Models will vary with the clinical condition
and its underlying mechanisms, and with the research hypothesis, where different combinations
of characteristics are possible. Most evidence supporting personalised nutrition has come from
observational studies with disease risk factors as outcomes (e.g., postprandial glucose response).
However, there are some trials using clinical endpoints that have incorporated participant information
to test prediction of responses [5] and large-scale studies collecting multi-dimensional data to predict
response to acute diet challenges [6].
Gut microbiota is one variable shown to be mechanistically relevant for a number of disease
states and therefore has a potential role in the development of personalised dietary advice. Microbiota
has a profound impact on our health, and alterations to its composition and its dysfunction have
been associated with several chronic diseases [7]. Despite the lack of a clear definition of a “healthy
microbiota”, its general hallmarks include its resistance to compositional change and its responsiveness
to environmental challenges [8]. This allows continuous operation of essential metabolic and immune
functions including host nutrient metabolism, maintenance of structural integrity of the gut mucosal
barrier, immunomodulation and protection against pathogens.
Diet is well known as one of the major drivers of microbiota composition [9] and conversely,
the microbiota response to dietary intervention varies between individuals [10]. In the last decade,
efforts have been directed to beginning to understand how biological response may be influenced by
the baseline microbiota [11]. Much of the research investigating the predictive capacity of baseline
microbiota for clinical response to dietary intervention has been reported in two specific health
conditions, namely, obesity and IBS.
1.1. Clinical Condition 1: Obesity
Overweight and obesity rates continue to rise worldwide. In 2013, among adults (age ≥20 years),
37% of men and 30% of women were considered overweight (BMI 25–29.9) or obese (BMI ≥30) [12].
Obesity is associated with numerous chronic diseases and increases the risk for type 2 diabetes,
metabolic disorder and cancer [13,14]. The pathogenesis of obesity is complex, with environmental,
sociocultural, behavioural, physiological, genetic and epigenetic factors known to be contributors.
Treatment often requires significant behaviour modification including dietary change and physical
activity. Common dietary approaches include a low-fat diet, a high-protein diet or the DASH (Dietary
Approaches to Stop Hypertension) diet [15,16]. Pharmacotherapy, medical devices and bariatric surgery
are other treatment options for patients requiring additional intervention. Given the multifaceted
nature of obesity, there is no single nor simple treatment solution, and therefore novel, and most likely
personalised, interventions may be necessary for effective treatment.
1.2. Clinical Condition 2: Irritable Bowel Syndrome
Irritable bowel syndrome (IBS), a chronic functional bowel disorder characterised by abdominal
pain and altered bowel habit [17], affects 11% of individuals globally [18]. Positive diagnosis is
based on the symptom profile meeting Rome IV criteria, and patients are classified into one of
four IBS subtypes (diarrhoea-predominant, constipation-predominant, mixed and unsubtyped) [17].
The pathophysiology of IBS is not completely elucidated. Most factors proposed are embodied with the
concept of a disturbed bidirectional brain–gut axis, including alterations in the central nervous system
(e.g., high prevalence of anxiety and depression), visceral hypersensitivity, increased gut epithelial
permeability, low grade inflammation and an altered microbiome.
Lifestyle advice, including healthy diet and exercise, is usually considered as first line therapy,
followed by symptom-directed pharmacotherapies (anti-spasmodics, laxatives, pro-secretory agents)
which have varying efficacy and safety profile [19]. The low FODMAP diet, an approach restricting
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the intake of specific fermentable carbohydrates (i.e., oligo-, di-, mono-saccharides and polyols) is a
second-line dietary intervention [20] and, although successful in inducing global symptom response in
many, is often not effective for up to 50% of patients [2].
1.3. Purpose of Review
Recent research suggests that dietary advice could be revolutionised towards a more personalised
approach for a spectrum of disease states. Accurate prediction of clinical response, such as weight
loss in obesity or symptom improvement in IBS, may not only improve short-term clinical response
but also long-term treatment efficacy and overall health outcomes in response to dietary intervention.
This paper aims to review the current state of evidence related to how knowledge of gut microbiota
may facilitate personalised dietary treatments in obesity and in IBS, with a focus on human dietary
intervention trials. In addition, the article aims to identify the knowledge gaps and address the
implications of research to date. Studies were selected for inclusion if they assessed baseline microbiota
composition as a prediction tool for the clinical response after dietary intervention in human cohorts
with IBS and obesity. Can gut microbiota composition predict response to dietary treatments?
1.4. Role of Intestinal Microbiota in Obesity
Several lines of evidence support a role for microbiota in the pathophysiology of obesity. The obese
mouse model is characterised by a 50% decrease in Bacteroidetes abundance, an increase in Firmicutes [21]
and a lower abundance of Akkermansia muciniphila [22] compared with lean mice. Clinical research in
humans supports this, with evidence of fewer Bacteroides and more Firmicutes [21], as well as a lower
abundance of Bifidobacteria [23] compared with lean controls. Obesity is also associated with a lower
bacterial richness (where richness is defined as the number of different species in an ecosystem) and
those with a lower bacterial richness gain more weight over time [24]. Efficacy of probiotics [25] and
faecal microbiota transplantation (FMT) [26] (via colonisation with “lean microbiota”) to induce weight
loss in obese individuals implies that attempts at “correcting” the microbial equilibrium can influence
body weight and adiposity in obesity.
Although the underlying mechanisms by which gut microbiota contributes to obesity are not fully
understood, evidence suggests contributing pathways include activity of the fermentation by-product
short-chain fatty acids (SCFAs) in regulating gut hormones and influencing energy harvest [27].
Gut microbiota may also suppress the production of fasting-induced adipose factors [28] and be linked
to inflammatory responses [29], regulation of lipogenesis pathways of triglyceride synthesis [30] and
impaired innate immune interactions [31].
1.5. Impact of Dietary Treatment on the Microbiome in Obesity
Energy restriction is the staple dietary intervention in obesity. When obese humans are assigned to
either a fat-restricted or carbohydrate-restricted diet, the resulting increase in abundance of Bacteroidetes
correlates with percentage loss of body weight [21]. Others demonstrate that three months of a
formula-based very low-calorie diet (800 kcal/day) in 18 obese adults led to 21 kg average weight
loss with concomitant changes in microbiota and bacterial metabolism [32]. The indicative taxa
for the microbial diversity change involved the increase in Acinetobacter. Furthermore, a six-week
energy-restricted high-protein diet in 38 obese adults improved low gene richness (i.e., number of
detected bacterial genes) and increased the abundance of most gene clusters [33]. Another study
assessed the impact of a Mediterranean diet compared with a low-fat diet in 20 obese men. There
were no significant differences in the metabolic variables measured (weight change was not reported)
between the diets after one year of dietary intervention. However, the low-fat diet group demonstrated
an increased relative abundance of Prevotella and decreased Roseburia genera from baseline, whereas the
Mediterranean diet led to the reverse, a decreased abundance of Prevotella and increased abundances
of the Roseburia and Oscillospira genera from baseline [34]. These diets led to differential alterations in
gut microbiota due to changes in food groups.
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In addition to energy restriction, dietary interventions designed to target gut microbiota have
used a range of potential modulators and have assessed various obesity risk factors. For example, one
prebiotic supplementation study showed that a 16-week intervention of oligofructose-enriched inulin
in overweight or obese children (7–12 years) led to a greater abundance of Bifidobacteria compared
with controls who received maltodextrin [35]. Many other within-group changes were observed for
microbiota, but importantly, changes in gut microbial abundance coincided with beneficial changes
in body composition and biological parameters of interleukin-6 and serum triglycerides compared
with controls. Others have studied the effect of prebiotics through food or whole diet interventions.
One uncontrolled trial delivered a diet rich in non-digestible carbohydrates (based on whole grains,
traditional Chinese medicinal foods and prebiotics) via hospitalised intervention in 21 morbidly
obese children (3–16 years) for 30 days [36]. Microbiota composition, which had been enriched with
potentially pathogenic bacteria at baseline, was much higher post-intervention in beneficial groups of
bacteria, such as Bifidobacterium spp. Structural changes at the individual bacterial genome level were
also significantly associated with improvements in host metabolic health (e.g., serum antigen load,
alleviation of inflammation) alongside the 9.5% loss of initial bodyweight [36].
1.6. Microbiome as a Predictor for Dietary Treatment Response in Obesity
In the last five years, there have been four relatively small dietary trials that assessed the association
of baseline microbiota with either weight response in obese cohorts or the response of postprandial
hyperglycaemia in healthy individuals, an independent risk factor for obesity. Furthermore, there have
been two studies that used microbiota as a prediction tool to model weight response in obesity cohorts
and two to predict glycaemic response in healthy individuals (Table 1).
First, a summary of the studies assessing weight response in obesity is presented. Two unrandomised
trials have demonstrated the utility of baseline microbiota in predicting bodyweight response to dietary
intervention. One showed that a higher gene richness at baseline was associated with a greater
reduction in adipose tissue and systemic inflammation after a six-week energy-restricted high-protein
diet (n = 38) [33]. The other reported that higher baseline abundance of Akkermansia muciniphila was
associated with greater improvement in insulin sensitivity and body fat distribution after a six-week
energy-restricted diet (n = 49) [37]. The first of two modelling studies implemented a six-week
energy-restricted, high-protein diet followed by a six-week period of weight maintenance in obese or
overweight individuals (n = 50) [38]. A combination of biological, gut microbiota and environmental
factors were used to predict individual weight loss trajectory using a graphical Bayesian network
framework. Those who lost the least weight and regained the most were characterised by higher
abundances of Lactobacillus, Leuconostoc and Pediococcus genera. The overall microbiota composition
at baseline was not identified by the framework as a predictor for weight loss. In another modelling
study, the likelihood of weight loss in 78 obese adults undertaking high-fibre dietary interventions was
related to the abundance of Firmicutes at baseline [39].
Key studies in the personalised nutrition field have investigated postprandial glycaemic responses
(PPGR) to dietary intervention. One crossover randomised clinical trial (RCT) randomised 39 healthy
participants to a three-day intervention of barley kernel-based bread or white wheat flour bread
(100 g starch/day). The 10 participants demonstrating the most pronounced improvement in glucose
and insulin response after a standardised breakfast following the barley kernel-based bread intervention
were classified as responders. Responders were characterised by a higher Prevotella/Bacteroides ratio,
higher relative abundance of Dorea and greater microbial potential to ferment complex oligosaccharides
at baseline compared with non-responders [40]. Also implementing a bread intervention, a second
RCT provided 20 healthy participants with three portions of 145 g sourdough-leavened whole-grain
bread or 110 g white bread per day for one week. The interpersonal variability in glycaemic response
to the different bread types could be reliably predicted with baseline microbiome data (accuracy ROC
curve of 0.83) [41].
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Table 1. Summary of recent trials reporting on the association between baseline gut microbiota composition and association with clinical response in obesity.
Study Study Design No. ofSubjects
Clinical
Condition Dietary Intervention Control Key Findings Ref.
Controlled trials – weight response
Cotillard
et al., 2013 Non-randomised clinical trial
49 (f = 41,
m = 8)
Obesity (n = 38,
and n = 11
overweight)
6-week energy-restricted
high-protein diet followed by a
6-week weight-maintenance diet
-
Responders: Higher gene richness (where
responders were those with marked
improvement of adipose tissue and systemic
inflammation).
[33]
Dao et al.,
2016 Non-randomised clinical trial
49 (f = 41,
m = 8)
Obesity and
overweight 3-week calorie restriction -
Responders: Higher gene richness and
Akkermansia muciniphila abundance was
associated with most improved body fat
distribution, fasting plasma glucose, plasma
triglycerides, improvement in insulin sensitivity.
[37]
Modelling studies – weight response
Kong et al.,
2013 Network modelling
50 (f = 42,
m = 8)
Obesity and
overweight
6-week energy-restricted,
high-protein diet followed by
maintenance phase
-
Responders: Baseline microbiota not identified as
a predictor. Non-responders: High
Lactobacillus/Leuconostoc/Pediococcus.
[38]
Korpela
et al., 2014 Predictive modelling
78 (f = 40,
m = 38)
3 cohorts with
obesity
3 different types of dietary
interventions varying in
carbohydrate quality and quantity
-
Responders: High abundance of Firmicutes,
where the microbiota composition was associated
with change in serum cholesterol levels.
[39]
Controlled trials – glycaemic response
Kovatcheva-
Datchary
et al., 2015
RCT, crossover 39 (f = 33,m = 6) Healthy 3-day barley kernel-based bread
3-day white
wheat flour
bread
Responders: Higher Prevotella/Bacteroides ratio
and increased Dorea that could predict PPGR to
barley kernel-based bread.
[40]
Korem et al.,
2017 RCT, crossover
20 (f = 11,
m = 9) Healthy
1 week of 3× 145 g whole-grain
sourdough/day
1 week of 3×
110 g refined
white
bread/day
Responders: Specific microbial signature
(especially abundances of Coprobacter fastidiosus
and Lachnospiraceae bacterium) could predict
PPGR to either bread.
[41]
Modelling studies – glycaemic response
Zeevi et al.,
2015 Machine learning algorithm
800
(f = 480,
m = 320)
Healthy (assessing
glycaemic
response)
1-week usual diet with one
standardised meal with 50 g
available carbohydrate/day
-
Responders: Proteobacteria, Enterobacteriaceae
and Actinobacteria were associated with elevated
PPGRs. Non-responders: Clostridia and
Prevotellaceae associated with lower PPGRs.
[6]
Mendes-Soares
et al., 2019
Same modelling framework
as Zeevi et al., 2015 [6]
327
(f = 255,
m = 72)
Healthy (assessing
glycaemic
response)
6-day usual diet including four
standardised meals with 50 g
available carbohydrate
-
Baseline microbiota combined with other
physiological characteristics was more predictive
of PPGR than using only calorie or carbohydrate
content of foods.
[42]
PPGR, postprandial glycaemic response; RCT, randomised clinical trial.
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The most impressive study that has investigated predictors of biological responses to diet to date
is a large predictive modelling study. Participants’ (n = 800) blood glucose was continuously monitored
for one week whilst they recorded daily activities and dietary intake [6]. The PPGR to the first meal of
every day, which was one of four different standardised meals (equivalent to 50 g carbohydrate), was a
key component of a large dataset of clinical, anthropometric, dietary and biological information. PPGR
variability was associated with a variety of clinical factors (HbA1c%, BMI, systolic blood pressure and
alanine aminotransferase (ALT) activity). However, intriguingly, Proteobacteria and Enterobacteriaceae
were positively associated with some of the PPGR to the standardised meal; associations with glycaemic
response were also evident for certain microbial pathways at the functional level. From these data,
a prediction model using thousands of decision trees based on 137 features representing meal content,
daily activity, blood parameters and microbiome features was then validated in a separate 100-person
cohort [6]. Similarly, others have used six-day PPGR data in 327 healthy participants to demonstrate
that baseline microbiome combined with other physiological characteristics is highly predictive of
postprandial responses. This was more predictive than standard clinical approaches that incorporate
calorie or carbohydrate content alone [42].
Together, the findings from the obesity cohorts and glycaemic response studies highlight that
microbiota composition and abundance of specific taxa present an exciting opportunity to enable
predicting responsiveness to diet. However, challenges in interpreting the evidence exist, including
the heterogeneity of studies, such as the length of dietary challenge (three to six weeks in obesity, three
days to one week in PPGR), the type and intensity of intervention (level of caloric restriction, types of
carbohydrate) and the number of taxa analysed. Most studies defined their subject cohort, including
presence of comorbidity and medication use; however, many did not report on other external factors
that could influence microbiota composition (e.g., probiotics), which may have contributed to the
heterogeneity of findings.
1.7. Role of Intestinal Microbiota in IBS
Evidence for microbiota in the development and/or as a driving force of symptom severity in IBS
has been accumulating for some 35 years. The line of evidence that is most well supported in the
literature is the observation that the faecal microbiota composition of patients differs from that of healthy
controls, although there is little consistency in findings across studies [43,44]. Reported differences
include a higher Firmicutes/Bacteroidetes ratio [45–49], a lower Bifidobacteria abundance [48,50–55] and
instability in response to dietary change [56] in IBS compared with healthy controls. Differences
have not been limited to the luminal compartment; colonic mucosal microbial composition also
deviates from healthy controls [46,51,57]. Distinct microbial profiles associated with severity of gut
symptoms [47–49,57,58] or presence of psychological morbidity [47,57–59] support a potential role for
microbiota in perpetuating symptoms. Although one of the most recent investigations of microbiota in
IBS identified a distinct faecal and mucosal signature associated with categories of symptom severity
in IBS [49], a unique and consistent microbial signature differentiating IBS from non-IBS has not
been identified.
A number of other lines of evidence supporting the important role of microbiota in the
pathophysiology of IBS come from animal models. The presence of transplanted microbiota from
individuals with IBS in germ-free mice leads to the transfer of the disease state, including altered
microbiota composition, visceral hypersensitivity, altered transit, immune activation and behavioural
manifestations of the condition [60,61]. Other animal data suggest microbial metabolites, such as
SCFAs, induce visceral hypersensitivity, a key feature of IBS [62]. In humans, additional support for the
involvement of microbiota in IBS aetiology is the presence of systemic and mucosal immune activation,
with the altered gut microbiota a potential key driver of this dysregulation [63]. Finally, although it is
still unclear whether a divergent microbiota is a primary phenomenon, the efficacy of therapies such
as probiotics and FMT implies that attempts at “correcting” the abnormality lead to at least partial
restoration of microbial and GI equilibrium [64,65].
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1.8. Impact of Dietary Treatment on the Microbiome in IBS
Over the past 10 years, clinical trials of the low FODMAP diet have vastly outnumbered studies
of other ”whole diet” interventions in IBS. Response rates of 50–80% are reported in RCTs in which
the advice is dietitian-led [2]. The impact of short-term FODMAP restriction on the faecal microbiota
has been reported in a number of trials of dietary advice in free-living individuals with IBS [65–69]
and in a highly controlled feeding trial [70]. A variety of taxonomic changes have been reported,
of which the most consistent finding is a lower relative or absolute abundance of Bifidobacteria
compared with controls and/or pre-intervention [65–67,69–71]. Interestingly, those individuals with
greater Bifidobacteria abundance at baseline exhibit the greatest depletion in response to FODMAP
restriction [65]. Altered metabolomic profile in response to FODMAP restriction has also been reported
in IBS, suggesting there is a change in metabolic activity of microbes in response to reduced availability
of fermentable carbohydrates or increased availability of alternative dietary substrates [67,71]. Whether
these microbial changes are key to inducing symptomatic response to a low FODMAP diet is not
known from the current evidence. The anti-bifidogenic effect of the low FODMAP diet is inconsistent
with a “more is better” hypothesis that could be postulated from the inverse correlation between
Bifidobacteria and symptom severity [48,57] and the trend toward efficacy of Bifidobacteria-containing
probiotic supplements in IBS [72].
1.9. Microbiome as a Predictor for Dietary Treatment Response in IBS
The ability to predict symptomatic response to the low FODMAP diet has been of recent interest,
particularly considering the diet is intensive to implement and requires dietetic supervision [73], and
that up to half of individuals may not benefit. There is limited but consistent evidence that baseline
demographic or clinical characteristics do not differentiate responders from non-responders to the low
FODMAP diet [68,74–76].
Five studies have investigated whether baseline microbiota could predict symptomatic response
to the low FODMAP diet (Table 2). One four-week RCT (19/33 responders, 61%) [5] and a four-week
uncontrolled trial (32/61 responders, 52%) [77] of low FODMAP dietary advice propose baseline
microbial profile to be predictive of response, using a microbial mapping technique based on selected
DNA probes [78]. Of the 45 bacterial markers at baseline in the latter trial, 10 differentiated responders
from non-responders with a positive predictive value of 76.0 (95% CI 61–87) using scores based on an
arbitrary microbial “response index”. A third study, a small uncontrolled one-week trial in children
(4/8 responders, 50%), reported that a lower abundance of saccharolytic Bacteroides and Bacteroidales
was predictive of dietary response [68]. This was followed by a crossover RCT (8/33 responders,
24%) that reported baseline enrichment of a range of saccharolytic taxa including Bacteroides and
Faecalibacterium prausnitzii in responders compared with non-responders [79]. However, not all studies
report positive findings; one trial found no predictive value of baseline microbiota in determining
clinical response to a low FODMAP diet, although the highly controlled four-week feeding RCT in
adults (11/27 responders, 41%) based findings on abundances of a select few taxa using qPCR analysis.
It must also be noted that both trials of crossover design may have influenced microbial composition
of those receiving low FODMAP diet as the second intervention [68,70].
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Table 2. Summary of recent trials reporting on the association between baseline gut microbiota composition and association with clinical response in IBS.
Study Study Design No. ofSubjects IBS Sub-Type
Dietary
Intervention Control Key Findings Ref.
Chumpitazi
et al., 2014
Dietary advice
uncontrolled trial
8 children
(f = 4, m = 4)
Paediatric
Rome III; all
IBS subtypes
included
Low
FODMAP -
Responders: Greater richness and diversity compared at
baseline compared with non-responders. Greater
abundance of Bacteroides, unclassified Ruminococcaceae
and Faecalibacterium prausnitzii at baseline compared with
non-responders.
[68]
Halmos
et al., 2015
Crossover feeding
RCT
27 (f = 21,
m = 6)
Rome III, all
IBS subtypes
included
Low
FODMAP
Typical
Australian
diet
No baseline microbiota differences identified between
responders and non-responders. [70]
Chumpitazi
et al., 2015
Crossover feeding
RCT
33 children
(f = 22,
m = 11)
Paediatric
Rome III; all
IBS subtypes
included
Low
FODMAP
American
childhood
diet
Responders: Greater abundances for a range of
saccharolytic taxa including within the family
Bacteroidoidaceae and order Clostridiales (e.g.,
F. Prausnitzii) compared with non-responders.
[79]
Bennet
et al., 2018
Dietary advice
RCT
61 (f = 51,
m = 10), 33
low FODMAP
Rome III; all
IBS subtypes
included
Low
FODMAP
Traditional
IBS diet
Responders: Increased abundance of Streptococcus, Dorea
and Ruminococcus gnavus at baseline compared with
non-responders. Lower dysbiosis index at baseline
compared with non-responders.
[5]
Valeur
et al., 2018
Dietary advice
uncontrolled trial
61 (f = 54,
m = 7)
Rome III, all
IBS subtypes
included
Low
FODMAP -
Responders: Greater abundance of Bacteroides fragilis,
Acinetobacter, Ruminiclostridium, Streptococcus and
Eubacterium at baseline compared with non-responders.
Lower abundance of Clostridia, Actinomycetales,
Anaerotruncus and Escherichia at baseline compared with
non-responders.
[77]
IBS, irritable bowel syndrome; RCT, randomised clinical trial.
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There are obvious challenges in interpreting the evidence from these trials. Pre-intervention
environmental factors (e.g., medication, probiotic intake) that could impact on baseline microbiota
composition are not always reported or controlled. Heterogeneity in baseline stool consistency
and psychological comorbidity, both associated with altered microbiota composition [47,80,81],
also complicate the identification of a distinct “responder” microbiota. Second, the stringency
of low FODMAP dietary advice varies between studies. Insufficient FODMAP restriction could lead to
an underestimation of true responders. Furthermore, clinical response criteria vary across studies,
ranging from validated criteria [5,77] through to arbitrary cut-offs [70], leading to a sizable range of
symptom severities in “responders” after low FODMAP treatment. Finally, no two studies so far have
utilised the same statistical modelling techniques to explore the potential of microbiota as a predictor;
ideally, the choice of statistical approach should be made by an independent blinded researcher to
enable objective and statistically rigorous findings.
Based on the literature thus far, there is inconsistent evidence to support the use of one baseline
microbiota signature to accurately predict response to a low FODMAP diet. Evidence that a baseline
bacterial volatile organic compound profile may very accurately select responders [82] suggests the
possibility that the metabolic function of bacteria may be important in determining response. Validation
studies in well-controlled studies of specific IBS subtypes are warranted.
2. General Discussion and Limitations
Few human studies (summarised in Tables 1 and 2) have been conducted investigating whether
specific microbial signatures predict response to dietary interventions. The conditions of obesity and
IBS represent the best examples of preliminary work conducted in this area. Based on this review,
there is inconsistent evidence to support the existence of specific microbiota signatures to accurately
predict clinical response to dietary intervention in obesity and IBS. A number of limitations still impede
progress in this sphere of research.
First, microbial sampling (i.e., faecal or biopsy) and quantification methodologies applied across
studies thus far have been inconsistent. The increasing power and sensitivity of modern sequencing
techniques has led to the rapid development of high-throughput methods for assessing genome-wide
genetic variations. However, the approaches used to characterise the human microbiota still vary
widely. Furthermore, technical accuracy is crucial throughout processing and analysis. For example,
the suboptimal mechanical lysis during extraction of the microbiota DNA from faecal or biopsy samples,
a key step in the analysis pipeline [83], will distort the downstream analysis more than any other
analysis step.
Second, there are several shortcomings in the predictive modelling analysis methods utilised.
Therefore, it is important that consistent analysis pipelines be adopted worldwide enabling comparison
of data between studies. Studies may be limited to exploratory statistical analysis until clinical studies
can be adequately designed and powered for primary analysis.
Third, there are many problematic confounding factors that can impact on baseline microbiota
composition. These factors include, but are not limited to, the host genetic makeup, long-term dietary
habits, ethnicity, sanitation, geographical location, exercise and lifestyle habits, and antibiotic use. This
further highlights the conclusion that any personalised predictive model incorporating gut microbial
composition must consider multiple additional relevant individual datapoints, which may vary with
disease state. It is also acknowledged that some chronic diseases, although benefiting from dietary
intervention, may never be amenable to a microbiota-based personalised nutrition approach due to
inherent heterogeneity in microbiota composition across individuals.
Finally, for ultimate translation into clinical practice, there is a need to understand if the results
gained from short-term studies predicting host response can be translated into durable responses over
time, leading to long-term positive health outcomes. Longer duration of studies and intervention
periods are also needed.
Nutrients 2019, 11, 1134 10 of 15
3. Conclusions
Diet is one of the most important determinants of the gut microbiota composition. However, the
relationship between diet and microbiota is complex and not completely understood. Consequently,
personalised nutrition models that predict clinical response to dietary treatment based on the microbial
composition are still extremely challenging to test in the research context. Some evidence of associations
between gut microbiota and response to dietary treatments for both obesity and IBS suggests that
links exist between microbiota composition and inter-individuality in host response to diet. However,
personalised nutrition research is in its infancy and specific microbiota signatures that predict
individualised responses to dietary treatment are still elusive; advancements in analysis technologies
and consistent bioinformatic approaches will be important for progress.
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Abbreviations
ALT Alanine aminotransferase
FMT Faecal microbiota transplant
FODMAP Fermentable oligo-, di-, monosaccharides and polyols
IBS Irritable bowel syndrome
PPGR Postprandial glycaemic response
RCT Randomised clinical trial
RNA Ribonucleic acid
SCFA Short-chain fatty acid
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